Src and focal adhesion kinase as therapeutic targets in cancer.
Over the past few years small molecule inhibitors of both Src family kinases and focal adhesion kinase (FAK) have entered clinical studies for the treatment of solid tumours. These adhesion-linked kinases are involved in a number of pathways that have impact on the behaviour of tumour cells and the challenge is now, how to take these forward in the clinical setting.
Brunton
Valerie G
VG
Institute of Genetics & Molecular Medicine, Division of Cancer Biology, University of Edinburgh, Crewe Road South, Edinburgh, United Kingdom. v.brunton@ed.ac.uk
Frame
Margaret C
MC
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D049109:Cell Proliferation / Q000187:drug effects; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects / Q000502:physiology; D019061:src-Family Kinases / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D051416:Focal Adhesion Protein-Tyrosine Kinases; D019061:src-Family Kinases